

## **Targets " >**

We have introduced new management targets covering environmental, social and governance (ESG) topics, in alignment with our company-level priority of building trust with society. The topics covered include environmental sustainability, pricing and access to medicines, global health challenges, ethics, risk and compliance.

Pricing and access

### **100% of new products launched to include an access strategy**

[Learn more about the Novartis Access Principles.](#)

### **Increase patients reached with strategic innovative medicines in low- and middle-income countries by at least 200% by 2025**

**Implement tiered pricing for launches in Pharmaceuticals and Oncology based on national income levels and value-based pricing**

**Achieve a twofold increase in the number of patients reached in sub-Saharan Africa by 2022, and a fivefold increase by 2025**

Global health challenges

**Increase patient reach of global health flagship programs in Leprosy, Malaria, Chagas Disease and Sickle Cell Disease (SCD) by 50% by 2025**

#### **Malaria**

Advance clinical development program for our next-generation antimalarials, KAE609 and KAF156.

[Learn more about our ongoing efforts against malaria](#)

#### **Sickle cell disease**

Expand Africa Sickle Cell Disease program rollout to five countries by end of 2020 and to 10 countries by 2022.

[Learn more about our ongoing efforts to fight sickle cell disease](#)

#### **Chagas disease**

Advance clinical development program for our heart failure medicine in patients with Chagas-related heart failure

[Learn more about our ongoing efforts against Chagas disease](#)

Ethics, risk and compliance

#### **Clinical trial transparency**

100% of clinical trial results posted on either clinicaltrials.gov or novartisclinicaltrials.com within one year of completion

[Learn more about our approach to clinical trial transparency](#)

#### **Third-party risk management (TPRM)**

- Third-party risk assessment conducted for 100% of new eligible suppliers

- Complete risk assessments of existing suppliers by 2022
- Fully integrate human. rights into third-party risk assessments in scope

[Learn more about our approach to third-party risk management](#)

## **Enhance external reporting on anti-bribery by 2022**

Responsible citizenship

### **Climate targets**

- 2025: Be carbon neutral in our own operations (Scope 1 and 2); Include environmental criteria in all supplier contracts
- 2030: achieve full carbon neutrality across the supply chain (Scope 1, 2, 3)

[Learn more about our efforts to reduce our impacts on climate](#)

### **Water targets**

- 2025: reduce water consumption in our operations by half versus 2016 baseline, with no water quality impacts from manufacturing effluents
- 2030: be water neutral in all areas of our operations, while actively enhancing water quality wherever we operate

[Learn more about our efforts to reduce our impacts on water](#)

### **Waste targets**

- 2025: eliminate polyvinyl chloride (PVC) in packaging (secondary and tertiary packaging; primary packaging when feasible) and reduce waste disposal by half versus 2016 levels
- 2030: be plastic neutral, with all new products meeting sustainable design principles

[Learn more about our efforts to reduce our impacts on waste](#)

### **Diversity and inclusion**

- Achieve gender balance in management by 2023
- Close the gender pay gap by 2023

[Learn more about Diversity & Inclusion at Novartis](#)

### **Training and development**

- Invest USD 100m in learning over the next five years from 2019

## **Results**

Explore our [Novartis in Society ESG report](#) to see how we performed in 2020.

[Learn more about our approach to ESG topics](#)

---

**Source URL:** <https://www.novartis.com/esg/reporting/targets>

### **List of links present in page**

- <https://www.novartis.com/esg/reporting/targets>

- <https://www.novartis.com/esg/access/novartis-access-principles>
- <https://www.novartis.com/diseases/malaria>
- <https://www.novartis.com/diseases/sickle-cell-disease>
- <https://www.novartis.com/diseases/chagas-disease>
- <https://www.novartis.com/clinicaltrials/transparency>
- <https://www.novartis.com/esg/ethics-risk-and-compliance/risk-management>
- <https://www.novartis.com/esg/environmental-sustainability/climate>
- <https://www.novartis.com/esg/environmental-sustainability/water>
- <https://www.novartis.com/esg/environmental-sustainability/waste>
- <https://www.novartis.com/about/diversity-inclusion>
- <https://www.novartis.com/investors/novartis-annual-reporting-suite>
- <https://www.novartis.com/esg>